Skip to main content Skip to main navigation menu Skip to site footer

Overexpression of Estrogen Receptor 1 (ESR-1) in metastatic prostate cancer

  • Lucky Frannata ,
  • Ery Kus Dwianingsih ,
  • Raden Danarto ,
  • Indrawarman ,


Introduction: Estrogen Receptor 1 (ESR1) expression has appeared to impact prostate cancer advancement significantly. This study aims to compare the expression of ESR-1 in BPH and prostate cancer.

Methods: The samples were collected from a single-center hospital from 2014 to 2020. We exclude samples in which RNA concentration is under the minimum standard allowance to proceed. Deparaffinize formalin-fixed paraffin-embedded and RNAs extraction by manufacturer’s protocol with slight modification was performed. The RNA expression was investigated by using quantitative real-time polymerase chain reaction. We categorized into Benign Prostate Hyperplasia (BPH), Non-Metastatic Prostate Cancer (Non-MPCa) and Metastatic Prostate Cancer (MPCa) groups. The One Way ANOVA was used to analyze the data.

Result: The 40 samples included 15 BPH, 6 non-metastatic prostate cancer, 19 metastatic prostate cancer. Expression of ESR1 in BPH (6.9 ± 3.8) compared to expression of ESR1 in MPCa (12.7 ± 9.5), and Non-MPCa (2.6 ± 1.0) shows a significant difference. Expression of ESR1 in Non-MPCa compared to MPCa also indicates a significant difference in which expression MPCa shows an increased level of ESR1 expression.

Conclusion: This study shows that ESR 1 has significant expression differences in Benign Prostatic Hyperplasia, non-Metastatic Prostate Cancer, and Metastatic Prostate Cancer. The highest ESR1 expression is found in Metastatic Prostate Cancer. In conclusion, higher ESR1 expression is related to metastatic prostate cancer.



  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians 2021; 71: 209–249.
  2. Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. European Urology 2020; 77: 38–52.
  3. Center MM, Jemal A, Lortet-Tieulent J, et al. International Variation in Prostate Cancer Incidence and Mortality Rates. European Urology 2012; 61: 1079–1092.
  4. Zhao Z, San M, Duprey J-LHA, et al. Detection of single nucleotide polymorphisms within a sequence of a gene associated with prostate cancer using a fluorophore-tagged DNA probe. Bioorganic & Medicinal Chemistry Letters 2012; 22: 129–132.
  5. Wang Y-M, Liu Z-W, Guo J-B, et al. ESR1 Gene Polymorphisms and Prostate Cancer Risk: A HuGE Review and Meta-Analysis. PLoS ONE 2013; 8: e66999.
  6. McIntyre MH, Kantoff PW, Stampfer MJ, et al. Prostate Cancer Risk and ESR1 TA, ESR2 CA Repeat Polymorphisms. Cancer Epidemiology Biomarkers & Prevention 2007; 16: 2233–2236.
  7. Sivoňová MK, Dobrota D, Dušenka R, et al. Effect of CYP17 and PSA gene polymorphisms on prostate cancer risk and circulating PSA levels in the Slovak population. Molecular Biology Reports 2012; 39: 7871–7880.
  8. Low Y-L, Taylor JI, Grace PB, et al. Phytoestrogen Exposure, Polymorphisms in COMT, CYP19, ESR1, and SHBG Genes, and Their Associations With Prostate Cancer Risk. Nutrition and Cancer 2006; 56: 31–39.
  9. Sun T, Lee G-SM, Werner L, et al. Inherited Variations in AR, ESR1, and ESR2 Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy. Cancer Epidemiology Biomarkers & Prevention 2010; 19: 1871–1878.
  10. Onsory K, Sobti RC, Al-Badran AI, et al. Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population. Molecular and Cellular Biochemistry 2008; 314: 25–35.
  11. Bosland M, Mahmoud A. Hormones and prostate carcinogenesis: Androgens and estrogens. Journal of Carcinogenesis 2011; 10: 33.
  12. Salonia A, Gallina A, Briganti A, et al. Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. Cancer 2011; 117: 5029–5038.
  13. Ozten N, Vega K, Liehr J, et al. Role of Estrogen in Androgen-Induced Prostate Carcinogenesis in NBL Rats. Hormones and Cancer 2019; 10: 77–88.
  14. Furic L, Lawrence MG, Risbridger GP. Pro-tumorigenic role of ERα in prostate cancer cells. Aging 2015; 7: 356–7.
  15. McPherson SJ, Hussain S, Balanathan P, et al. Estrogen receptor–β activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent, and TNFα mediated. Proceedings of the National Academy of Sciences 2010; 107: 3123–3128.
  16. McPherson SJ, Ellem SJ, Simpson ER, et al. Essential Role for Estrogen Receptor β in Stromal-Epithelial Regulation of Prostatic Hyperplasia. Endocrinology 2007; 148: 566–574.
  17. Fixemer T, Remberger K, Bonkhoff H. Differential expression of the estrogen receptor beta (ER?) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. The Prostate 2003; 54: 79–87.
  18. Bonkhoff H, Berges R. The Evolving Role of Oestrogens and Their Receptors in the Development and Progression of Prostate Cancer. European Urology 2009; 55: 533–542.
  19. Horvath LG, Henshall SM, Lee C-S, et al. Frequent Loss of Estrogen Receptor-β Expression in Prostate Cancer1. Cancer Research 2001; 61: 5331–5335.
  20. Butler MJ, Hildebrandt RP, Eckel LA. Selective activation of estrogen receptors, ERα and GPER-1, rapidly decreases food intake in female rats. Hormones and Behavior 2018; 103: 54–61.
  21. Piperigkou Z, Karamanos NK. Estrogen receptor-mediated targeting of the extracellular matrix network in cancer. Seminars in Cancer Biology 2020; 62: 116–124.
  22. Cowley SM, Hoare S, Mosselman S, et al. Estrogen Receptors α and β Form Heterodimers on DNA. Journal of Biological Chemistry 1997; 272: 19858–19862.
  23. Chae YK, Huang H-Y, Strickland P, et al. Genetic Polymorphisms of Estrogen Receptors α and β and the Risk of Developing Prostate Cancer. PLoS ONE 2009; 4: e6523.
  24. Quintas-Granados LI, Cortés H, Carmen MG-D, et al. The high methylation level of a novel 151-bp CpG island in the ESR1 gene promoter is associated with a poor breast cancer prognosis. Cancer Cell International 2021; 21: 649.
  25. Royuela M, de Miguel MP, Bethencourt FR, et al. Estrogen receptors and in the normal, hyperplastic and carcinomatous human prostate, (2001).
  26. Modugno F, Weissfeld JL, Trump DL, et al. Allelic Variants of Aromatase and the Androgen and Estrogen Receptors: Toward a Multigenic Model of Prostate Cancer Risk1. Clinical Cancer Research 2001; 7: 3092–3096.
  27. Bonkhoff H, Berges R. The Evolving Role of Oestrogens and Their Receptors in the Development and Progression of Prostate Cancer. European Urology 2009; 55: 533–542.
  28. Ricke WA, McPherson SJ, Bianco JJ, et al. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. The FASEB Journal 2008; 22: 1512–1520.
  29. Mishra S, Tai Q, Gu X, et al. Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer. Oncotarget 2015; 6: 44388–44402.

How to Cite

Lucky Frannata, Ery Kus Dwianingsih, Raden Danarto, & Indrawarman. (2022). Overexpression of Estrogen Receptor 1 (ESR-1) in metastatic prostate cancer. Indonesia Journal of Biomedical Science, 16(1), 47–50.




Search Panel